HONG JING BIOTECH INC.
Update：2026/11/10
Industries
Main Industry
Biotechnology
Main Product/Service
Molecular Diagnostic Services in the Field of Oncology and Hematology
The content above was translated by Ai
Founded Year
2013
Unified Business No.
54035934
Status
Active
Number of Employees
28
Total Paid-in
Capital
12,000,000 (NT$)
Location of Company
Taiwan
, New Taipei City
Company names, registration status, legal representatives, founding years, paid-in capital, registered addresses, and other details are sourced from business registration records maintained by Taiwan’s Administration of Commerce, Ministry of Economic Affairs. Exit status includes Emerging Stock Board listings, M&A, and IPOs. Information on overseas expansion is self-reported by startups.
Note 1: FINDIT compiles company information from public and other sources for reference and does not serve as a point of contact for the companies listed.
Note 2: Some company profiles and product/service descriptions are translated using AI and provided for reference only. In case of discrepancies or ambiguity, the original text prevails.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
Femtopath is a global brand under Taiwan's HONG JING BIOTECH INC., primarily focusing on molecular diagnostics in the fields of oncology and hematology. We are committed to designing and producing mutation-specific oligonucleotide primers, providing users with high-sensitivity mutation enrichment technology. One of the key features of our technology is reversing the mutant/wild-type ratio through PCR. In Sanger sequencing, our customers are able to determine the mutation types in various sample types (such as FFPE, body fluids, blood, FNA, and cell blocks).
The content above was translated by Ai
